We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 21

Fundamentals of Canadian product liability - duty to warn
  • Gowling WLG
  • Canada
  • October 4 2011

A manufacturer has a duty to warn consumers and others in the supply chain of all material risks of which it is aware, or of which it ought to be aware, resulting from ordinary use of its product.


Data protection in Canada: too much? Too little?
  • Gowling WLG
  • Canada
  • June 28 2011

Prior to the enactment in 2006 of the amendments to section C.08.004.1 of the Food and Drugs Regulations (Data Protection Regulations), Canada did not have an effective regime of data protection exclusivity.


Provinces and territories discuss joining forces to purchase drugs at lower prices
  • Gowling WLG
  • Canada
  • August 26 2010

On August 6, 2010, Canadian Premiers attended their annual Council of the Federation Premiers' Conference in Winnipeg to discuss a joint alliance among the provinces and territories for purchasing common drugs and medical supplies and equipment for the public sector.


New decision on freedom of information re: product listing agreements
  • Gowling WLG
  • Canada
  • July 13 2010

On June 28, 2010, the Information and Privacy Commissioner of Ontario released a decision in Appeal Number PA08-294-2, which pertains to disclosure of Schedules to a product listing agreement between an unidentified drug company (the "affected party") and the Executive Officer of the Ontario Public Drug Programs ("OPDP").


Health Products & Food Branch policy on counterfeit health products
  • Gowling WLG
  • Canada
  • May 21 2010

By a document posted May 14, 2010, the Health Products & Food Branch Inspectorate have set out guiding principles of Health Canada's decision making framework for identifying, assessing and managing health risks to identify the issues of counterfeit health products.


First PMPRB decision dismissing allegations of excessive pricing
  • Gowling WLG
  • Canada
  • April 20 2010

The Patented Medicine Prices Review Board ("PMPRB") recently released its decision in the matter of Hoechst Marion Roussel Canada Inc. and the medicine NIOCODERM, a nicotine patch which assists those who are attempting to quit smoking; it is to be publicly posted on the PMPRB website today.


Second phase of Alberta's pharmaceutical strategy aims to reduce drug costs, improve access to new drugs and expand the role of pharmacists
  • Gowling WLG
  • Canada
  • November 2 2009

On October 20, 2009, the Alberta Government released the second phase of the Alberta Pharmaceutical Strategy which indicates that the Government will reduce generic drug prices - the Government states it will reduce the price of new generic drugs from 75 percent of the brand name drug to 45 and announces that its discussions with pharmacists and pharmacies regarding the price reduction will begin this month.


FDA clinical trial regulations - "Sentinal System"
  • Gowling WLG
  • USA
  • May 29 2008

On Thursday May 22, 2008, U.S. health officials announced that the FDA will implement a proactive system designed to help identify dangers associated with prescription drugs and medical devices that are currently on the market.


New regulations respecting benefits and promotional allowances in Québec
  • Gowling WLG
  • Canada
  • November 16 2007

The Government of Québec has introduced new regulations under the Act Respecting Prescription Drug Insurance governing the rebates and other benefits offered by drug manufacturers to pharmacists.


Mary M. Thomson
  • Gowling WLG